MS patients may soon get a simpler shot option
NCT ID NCT07609719
First seen May 29, 2026
Summary
This study looks at whether people with multiple sclerosis can safely switch from their current anti-CD20 therapy to a new under-the-skin version of ocrelizumab. About 100 participants will be followed for up to 48 weeks to see if brain lesions stay stable and if they are satisfied with the treatment. The goal is to offer a more convenient option for managing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advanced Neurology of Colorado
Fort Collins, Colorado, 80528, United States
-
Alabama Neurology Associates
Birmingham, Alabama, 35209, United States
-
Caribbean Center for Clinical Research
Guaynabo, 00968, Puerto Rico
-
Clinical Endpoints
Scottsdale, Arizona, 85258, United States
-
DHR Health MS Center
McAllen, Texas, 78501, United States
-
Minneapolis Clinic of Neurology
Minneapolis, Minnesota, 55422, United States
-
MultiCare Institute for Research & Innovation
Tacoma, Washington, 98405, United States
-
Multiple Sclerosis Center of Atlanta/Atlanta Neuroscience Institute
Atlanta, Georgia, 30327, United States
-
Neurology Associates - Maitland
Orlando, Florida, 32751, United States
-
Neurology Clinic, P.C.
Cordova, Tennessee, 38018, United States
-
Ohio State University, Multiple Sclerosis and Neuroimmunology Center
Columbus, Ohio, 43210, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ocrelizumab combined with recombinant human hyaluronidase (rHuPH20) given as a shot under the skin
What this could lead to
If it works, this could offer a more convenient way to control multiple sclerosis with fewer clinic visits.
What could go wrong
This is a small, early-phase study with no placebo group, so results may not apply broadly. Switching therapies could also cause unexpected side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.